BioSpace News Archive

Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 11:15 a.m. ET on Tuesday, March 19, 2024.

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit, announced that it will be participating in partnership meetings and exhibiting its CDMO services at the BIO-Europe Spring 2024 conference, taking place March 18 to 20 in Barcelona.

Halia Therapeutics today announced that David J. Bearss, Ph.D., President and CEO of Halia Therapeutics, will present at the BIO-Europe Spring 2024 Conference on Tuesday, March 19.

Rigel Pharmaceuticals, Inc. announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer.

Rallybio Corporation today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on recent program and corporate developments.

IDRx, Inc. announced that it has strengthened its leadership team with the appointments of Tim Clackson, Ph.D. as Chief Executive Officer, and Brad Dahms as Chief Financial Officer and Chief Business Officer.

Pearl Bio today announced that it has entered a license, collaboration and option agreement with Merck, known as MSD outside of the United States and Canada, to discover biologic therapies comprising non-standard amino acids.

Mainstay Medical Holdings plc announced the publication of a pooled analysis of three different clinical studies that evaluated the safety and efficacy of ReActiv8 therapy after two years in patients of various ages.

GenScript Biotech Corporation (HK.1548), a world’s leading technology and service provider of life science R&D and manufacturing, announced its annual results for the year ended December 31, 2023.

SOTIO Biotech today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.